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Sleep disruption is common among hematopoietic cell transplant (HCT) recipients, with over 50% of re-
cipients experiencing sleep disruption pre-transplant, with up to 82% of patients experiencing moderate to
severe sleep disruption during hospitalization for transplant and up to 43% after transplant. These rates of
sleep disruption are substantially higher than what we see in the general population. Although sleep
disruption can be distressing to patients and contribute to diminished quality of life, it is rarely discussed
during clinical visits. The goal of the current review is to draw attention to sleep disruption and disorders (ie,
insomnia, obstructive sleep apnea, restless legs syndrome) as a clinical problem in HCT in order to facilitate
patient education, intervention, and research. We identiﬁed 35 observational studies published in the past
decade that examined sleep disruption or disorders in HCT. Most studies utilized a single item measure of
sleep, had small sample size, and included heterogeneous samples of patients. Six studies of the effects of
psychosocial and exercise interventions on sleep in HCT have reported no signiﬁcant improvements. These
results highlight the need for rigorous observational and interventional studies of sleep disruption and dis-
orders in HCT recipients..
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION staying asleep, awakening earlier than intended, and/or
The number of both autologous and allogeneic hemato-
poietic cell transplants (HCTs) has increased dramatically in
recent years, with more than 50,000 performed worldwide
each year [1]. This increase in HCT is due to a greater number
of indications for its use as well as advances in therapy,
including more frequent use of peripheral blood stem cells,
reduced-intensity conditioning regimens, greater use of cells
from unrelated and alternative donors, improvements in
supportive care, and advances in histocompatibility typing.
Survival has generally improved as well [1], resulting in a
growing number of patients living with the short- and long-
term side effects of HCT.
Sleep disruption is frequently overlooked as a side effect
of HCT. Sleep disruption includes difﬁculty falling asleep,edgments on page 1482.
quests: Heather S. L. Jim, PhD, Depart-
havior, Mofﬁtt Cancer Center, MRC-PSY,
3612.
ofﬁtt.org (H.S.L. Jim).
2014 American Society for Blood and Marrow
14.04.010nonrestorative sleep [2]. It can occur without a clinical
diagnosis of a sleep disorder, although a clinical diagnosis
may be warranted if sleep disruption is chronic and impairs
daily functioning. Sleep disruption is common after HCT,
distressing to patients [3], and associated with greater fa-
tigue and reduced quality of life [3,4]. Nevertheless, sleep
disruption is seldom the focus of patienteprovider commu-
nication. A survey of 180 HCT physicians found that only 17%
discussed sleep with their patients during at least half of
clinical visits [5].
The goal of the current review is to draw attention to
sleep disruption as a clinical problem in HCT and to provide
clinicians and researchers with an overview of current evi-
dence to facilitate diagnosis, patient education, intervention,
and research. The review begins with a brief discussion of the
assessment and clinical diagnosis of sleep disruption and
common sleep disorders (ie, insomnia, obstructive sleep
apnea [OSA], and restless legs syndrome [RLS]). We then
synthesize and critically review evidence regarding theTransplantation.
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disorders in patients before HCT, during the acute trans-
plantation phase, and early, middle, and long-term survi-
vorship. This review focuses on HCT studies published in the
past decade to ensure greater relevance to current transplant
practices. Sociodemographic and clinical risk factors are
described, with an emphasis on those relevant to HCT. We
conclude with recommendations for management of sleep
disruption and disorders in the transplant setting as well as
directions for future research.
ASSESSMENT OF SLEEP DISRUPTION
Objective and self-report measures of sleep disruption
have been developed to facilitate differential diagnosis and
to monitor sleep over time. The gold standard for objective
measurement is polysomnography, which measures multi-
ple biologic processes of sleep, including electrical activity in
the brain and heart, limb movement, and eye movement. In
addition to collecting essential data for diagnosing sleep
disorders, polysomnography allows for the additional
advantage of monitoring the progression of sleep stages (eg,
rapid eye movement sleep or dreaming) and brain arousal
during sleep, which can elucidate the occurrence of sleep
interruptions. It is typically conducted in a sleep lab or hos-
pital, although home-based polysomnography is increasingly
used because of its lower cost.
An alternative to polysomnography is actigraphic moni-
toring in which a small, nonintrusive piezoelectric monitor
similar to a wristwatch is worn on the nondominant wrist to
detect and record motion. Specialized software is used to
determine sleep versus waking using algorithms validated
against polysomnography. Actigraphy data, in combination
with patients’ self-reports of bedtime and rising time, have
been found to be a reliable and valid measure of circadian
sleep patterns [6]. Parameters assessed include time in bed
asleep, time until sleep onset, number and length of night-
time awakenings, number and length of daytime naps, and
circadian variation in sleep and activity. Periodic limb
movement can also be assessed. Actigraphs are relatively
inexpensive and can be worn at home or in the hospital for
several days or weeks, enabling the naturalistic study of
sleep disruption over time. Actigraphy is typically used for
research rather than diagnostic purposes.
Despite the widespread availability of polysomnography
and actigraphy, to our knowledge only 1 study in HCT pa-
tients has been published using these measures to assess
sleep [7]. Thus, objective sleep patterns of HCT patients are
largely unknown.
Regarding self-report measures of sleep, several have been
validated in cancer patients [8,9]. The most common are the
Insomnia Severity Index [10] and the Pittsburgh Sleep Quality
Index [11]. These measures typically ask patients to estimate
how long it takes them to fall asleep, how many hours they
sleep each night, their use of sleep medications, and their
perceptions of sleepquality. Additionalmeasures used include
the Epworth Sleepiness Scale [12] to evaluate daytime sleep-
iness and the International Restless Legs Syndrome Study
Group rating scale to evaluate RLS symptomatology [13].
In addition to self-report measures, sleep diaries can play
an important role in research and clinical diagnosis. Patients
are typically asked to ﬁll out the diary on a daily basis for
several days or weeks. Requested information includes
bedtime and rising times as well as duration of sleep, sleep
quality, difﬁculty initiating and maintaining sleep, daytime
napping, medications taken, and other details [14,15]. Diariescan be particularly useful in both the research and clinical
settings for obtaining detailed information regarding patterns
of disruption, contributing factors, and targets of intervention.
CLINICAL DIAGNOSIS OF SLEEP DISORDERS
Guidelines for clinical evaluation of sleep disorders
depend on the disorder under consideration. Regarding
insomnia, diagnosis is based on a detailed sleep, medical,
substance, and psychiatric history in addition to a physical
and mental status examination. Sleep diaries are often used
as well. The goal is to establish the type and evolution of
insomnia, perpetuating factors, extent of daytime dysfunc-
tion, and identiﬁcation of comorbid medical, substance, and/
or psychiatric conditions [16].
Diagnostic criteria for insomnia include (1) difﬁculty
initiating sleep, maintaining sleep, and/or early morning
awakening with the inability to return to sleep; (2) signiﬁ-
cant distress and/or impairment in functioning; (3) sleep
difﬁculty that occurs at least 3 nights a week for at least
3 months; (4) sleep difﬁculty that occurs despite adequate
opportunity to sleep; and (5) symptoms that cannot be
explained by another mental or medical disorder [2].
Regarding OSA, a sleep history and physical exam
including symptoms and risk factors (eg, snoring, gasping/
choking at night, daytime sleepiness, obesity, type 2 dia-
betes, congestive heart failure, treatment-refractory hyper-
tension) are indicated [17]. Patients deemed to be at high risk
should then be evaluated using polysomnography or home-
based monitoring for deﬁnitive diagnosis [17]. Criteria for
diagnosis are (1) evidence by polysomnography of at least 5
apneas or hypopneas per hour of sleep (ie, snoring, snorting/
gasping, breathing pauses); (2) daytime sleepiness, fatigue,
or unrefreshing sleep despite sufﬁcient opportunity for
sleep; (3) symptoms are not better explained by another
mental or sleep disorder or medical condition; or (4) evi-
dence by polysomnography of 15 or more obstructive apneas
and/or hypopneas per hour of sleep regardless of accompa-
nying symptoms [2].
Regarding RLS, diagnosis is based primarily on self-report,
although polysomnography and actigraphy can be used [18].
Diagnostic criteria for RLS are (1) an urge to move the legs
accompanied by or in response to uncomfortable and un-
pleasant sensations in the legs; (2) the urge begins or
worsens during periods of rest or inactivity, is partially or
totally relieved by movement, and is worse or occurs only in
the evening or at night; (3) symptoms occur at least 3 times a
week for 3 months; (4) symptoms are accompanied by sig-
niﬁcant distress and/or impairment in functioning; and (5)
symptoms are not attributable to another mental or medical
disorder [2].
SLEEP DISRUPTION AND DISORDERS BEFORE
TRANSPLANT
Research on sleep disorders before HCT is limited to case
studies of lymphomas presenting as OSA (eg, [19]). In addi-
tion, a study of polysomnography in 12 multiple myeloma
patients receiving high-dose chemotherapy [7] reported
greater respiratory events and lower-than-normal levels of
arterial oxygen saturation, on average. Periodic limb move-
ments in the sample were high and increased during the
course of chemotherapy. No studies have reported on the
incidence or prevalence of pretransplant sleep disorders.
Numerous precipitating factors can contribute to sleep
disruption in patients before transplant. Patients typically
undergo several rounds of standard-dose chemotherapy that
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Side effects of chemotherapy, such as peripheral neuropathy,
may also contribute to sleep disruption [20]. Among cancer
patients treated with standard-dose chemotherapy, the
prevalence of RLS was 18% (double that of the general pop-
ulation), with longer chemotherapy associated with greater
risk of RLS [21]. In addition, many patients have elevated
levels of anxiety and depressive symptomatology [22]; anx-
iety can contribute to sleep disruption, whereas both
insomnia and hypersomnia are symptoms of depression and
share some common etiology [2].
Regarding the prevalence of sleep disruption outside the
context of a diagnosable sleep disorder, 16 studies have
examined sleep before transplantation (Table 1). Of these, 9
studies did not provide estimates of prevalence of sleep
disruption or comparisons to individuals not receiving HCT
[7,23-30]. The remaining 7 studies are heterogeneous in
terms of their sample composition, sample size, measure of
sleep, and clinical cut-off [3,4,31-35]. Thus, it is not surpris-
ing that there is substantial heterogeneity among study
ﬁndings. Studies using single-item measures of sleep
disruption suggest that approximately 8% of autologous pa-
tients report moderate to severe sleep disruption [31],
whereas more than 50% of allogeneic patients report sleep
disruption of any severity [3]. In contrast, the 2 studies using
validated measures (ie, Pittsburgh Sleep Quality Index and
Epworth Sleepiness Scale) found that 32% of patients re-
ported clinically signiﬁcant sleep disruption before autolo-
gous or allogeneic transplant [4] and 43% of multiple
myeloma patients reported clinically signiﬁcant daytime
sleepiness before autologous transplantation [35]. A direct
comparison of sleep disruption between patients receiving
allogeneic versus autologous HCT using a single-item mea-
sure suggested that sleep was signiﬁcantly better among
allogeneic patients, although sample sizes were small and
ﬁndings were confounded by group differences in diagnosis
and remission status [33]. Comparisons between HCT patient
and population norms are mixed, with 1 large study
reporting that patients reported signiﬁcantly worse sleep
before autologous transplant or treatment withmelphalan or
prednisone [32], whereas 2 smaller studies found no differ-
ences, perhaps due to low statistical power [33,34]. In sum-
mary, although ﬁndings are mixed, available data suggest
that sleep disruption before transplant is common but rela-
tively mild on average.
SLEEP DISRUPTION AND DISORDERS DURING THE ACUTE
TRANSPLANT PERIOD
The ﬁrst 100 days post-transplant are typically charac-
terized by multiple acute side effects of the conditioning
regimen, including mucositis, enteritis, nausea and emesis,
episodes of delirium, and, in the case of allogeneic transplant,
acute graft-versus-host disease (GVHD) and immunosup-
pressive therapies. These side effects and their treatment
may disrupt sleep [36]. Moreover, these side effects
frequently occur in the context of hospitalization, which can
have an additive effect on disrupted sleep [4]. Consequently,
sleep disruption tends to be most pronounced in the ﬁrst
100 days post-transplant. The most extensive research on
sleep disruption in HCT patients has also been conducted
during this period [3,4,24-26,30-32,37-39], although it is
characterized by several limitations, including small sam-
ples, which are heterogeneous in terms of diagnosis and
transplant type as well as low statistical power. In addition,
data are lacking regarding the prevalence and onset of sleepdisorders during this time, with the exception of 1 study
reporting a prevalence rate of clinically signiﬁcant insomnia
of 26% [37]. Available data suggest that sleep disruption was
the most distressing symptom among allogeneic HCT re-
cipients at day 0 and was signiﬁcantly correlated with bowel
changes and fatigue [3]. Sleep disruption signiﬁcantly
increased during the ﬁrst 100 days, with greatest disruption
seen during the conditioning regimen and WBC count nadir
[31]. Mean changes of 27 points on the European Organiza-
tion for Research and Treatment of Cancer Quality of Life
Questionnaire Core 30 sleep disruption item were observed
from pretransplant baseline to its peak approximately
2 weeks after HCT [25], corresponding to a large increase and
effect size of 1.1 standard deviations (SDs) [25]. These data
are consistent with a quantitative review of all published
studies using the European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire Core 30 to
assess quality of life in HCT patients, which found large in-
creases in sleep disruption during hospitalization [26].
Difﬁculty maintaining sleep was the most common
problem in hospitalized HCT patients (82%), followed by
nonrestorative sleep (61%), problems falling asleep (52%),
difﬁculties falling back to sleep once awake (48%), and early
morning awakening (21%) [4]. Patients largely attributed
these problems to the hospital environment, such as noise
from medical equipment and nursing staff, and to emotional
agitation and stress [4,37]. A small study found that alloge-
neic transplant patients reported better sleep before trans-
plant but worse sleep during hospitalization [4]. At the time
of hospital discharge, the average severity of sleep disruption
among allogeneic and autologous patients was still moder-
ately elevated relative to baseline symptomatology (ie, .51
SD) [26]. Nevertheless, it appeared that increases in sleep
disruption were generally transient; by day 100, sleep
disruption returned to levels comparable with pre-HCT
[4,25,31], although these levels were substantially elevated
even before the transplant. Patients receiving allogeneic HCT
demonstrate similar levels of sleep disruption near day 100
to patients receiving autologous transplant [4].
SLEEP DISRUPTION AND DISORDERS AFTER THE ACUTE
TRANSPLANT PERIOD
New precipitating factors of sleep disruption may occur
after the acute transplant period. Patients who experienced
resolved sleep disruption or never experienced sleep
disruption during transplantation may develop late-onset
sleep problems due to corticosteroid treatment for chronic
GVHD, inﬂammation due to GVHD or infection, fear of dis-
ease progression, pain, or additional treatments for relapsed
disease. For example, evidence suggests that long-term
corticosteroid use is a risk factor for OSA, perhaps because
of weight gain [40]. Insomnia is also a common side effects of
taking corticosteroids, particularly if the medication is taken
closer to bedtime. Muscle cramps and neuropathy have been
found to be common among patients with GVHD and to
disrupt sleep [41]; neuropathy is also a risk factor for RLS
[42]. These factors and others can also perpetuate existing
sleep problems and contribute to the development of
persistent (lasting more than 3 months) or recurrent sleep
problems. Additional perpetuating factors of insomnia
include cognitive distortions and maladaptive behaviors that
begin in reaction to a stressor and persist after the stressor is
resolved [43]. Examples of cognitive distortions that can
make sleep disruptionworse are as follows: “I’mgoing to feel
terrible tomorrow if I don’t sleep well” or “I’m never going to
Table 1
Observational Studies of Sleep in HCT Recipients
Study Sample Demographics Time Frame Sleep Measures Statistical Analyses Main Relevant Findings
Anderson et al.
(2007) [31]
Auto-HCT (N ¼ 100)
Included both disease-free and
relapsed patients
NHL (34%), MM (66%)
Age:
Mean ¼ 53.6 (9.7)
Range ¼ 24-75
Gender:
M ¼ 60%
F ¼ 40%
Race:
Caucasian ¼ 81%
African American ¼ 12%
Hispanic ¼ 5%
Other ¼ 2%
Longitudinal; 5
assessments: pre-HCT, 3rd-
4th day of conditioning, day
0, nadir, day 30
MDASI-BMT (a single-
item measure of sleep
disruption)
Repeated measures
ANOVA
The percentage of patients
reporting disturbed sleep at
moderate or severe levels at
each time point were as
follows: 8% at baseline, 34%
at conditioning, 39% at
nadir, 14% at day 30.
8% reported sleep
disruption at baseline, 34%
at conditioning, 26% at
transplant, 39% at nadir,
and 14% at day 30.
Sleep disruption was one of
most severe symptoms at
nadir, returned to pre-HCT
levels by day 30 post-HCT
Sleep disruption was
signiﬁcantly worse for NHL
thanMMpatients (P¼ .024)
Andrykowski et al.
(2005) [48]
HCT survivors (N ¼ 662) and
age- and sex-matched healthy
control subjects (N ¼ 158)
Allo (41%), auto (59%),
missing (1%)
AML (29%), CML (19%), ALL (7%),
Breast cancer (23%), lymphoma
(20%), other (1%)
Mean age: 50.1 (14.2)
Gender:
M ¼ 30%
Race:
White ¼ 95%
Cross-sectional; mean of
7 yr (84 mo) post-HCT
(inclusion criteria: >12 mo
post-HCT)
MOS-Sleep MANOVA (univariate
analyses)
HCT survivor group
reported more sleep
problems than healthy
control group (effect size ¼
.39, P < .001).
Bevans et al.
(2008) [3]
Allo-HCT (N ¼ 76)
RIC (54%), myeloablative (46%)
Included patients in remission
and with progressive disease
Acute leukemia (17%), chronic
leukemia (38%), lymphoma or
MM (29%), MDS (12%),
nonhematologic malignancy
(4%)
Mean age: 40.2 (13.5)
Gender:
M ¼ 67%
F ¼ 33%
Race:
White ¼ 46%
Hispanic ¼ 30%
Asian ¼ 9%
Black ¼ 7%
Other ¼ 8%
Longitudinal; baseline
(before transplant
conditioning), day 0, day
30, day 100
Symptom Distress Scale Univariate descriptive
analyses
At baseline, approximately
55% of patients reported
insomnia, 86% had
insomnia at day 0, nearly
70% had insomnia at day 30,
and at day 100 insomnia
levels went down to
baseline levels.
Insomnia was the most
distressing symptom at day
0 (reported by 32% of
participants).
Bieri et al. (2008) [49] Allo-HCT (N ¼ 124)
AML (n¼ 40), ALL (n¼ 20), CML
(n ¼ 31), CLL (n ¼ 1), MDS
(n ¼ 8), lymphoma (n ¼ 14),
MM (n ¼ 1), MPS (n ¼ 3), AA
(n ¼ 6)
Age:
Median ¼ 34
Range ¼ 14-65
Gender:
M ¼ 79
F ¼ 45
Cross-sectional; median of
7.3 yr post-HCT
EORTC QLQ-C30 Descriptive statistics,
t-test
Signiﬁcantly higher sleep
disruption among HCT
patients compared with
Norwegian population
norms. Unclear where
normative data came from.
Difference of .33 SD.
Univariate analysis
indicated that employment
status was associated with
sleep disruption.
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Bishop et al.
(2007) [50]
HCT (N ¼ 177), partners (N ¼
177), control subjects (N ¼ 133)
Allogeneic ¼ 78 (44%),
Autologous ¼ 99 (56%)
AML or ALL (39%), CML (22%),
breast cancer (18%), lymphoma
(21%)
Mean age: 50 (10)
Gender:
F ¼ 50%
Race:
White ¼ 94%
Cross-sectional; mean of
7 yr (84 mo) post-HCT
(inclusion criteria: >12 mo
post-HCT)
MOS-Sleep Mixed Effect
Linear Models
Patients showed
signiﬁcantly higher rates of
sleep problems than control
subjects (ES ¼ .39).
Partners showed
signiﬁcantly higher rates of
sleep problems than control
subjects (ES ¼ .22).
Boland et al.
(2013) [60]
Auto-HCT (n ¼ 29), allo-HCT
(n ¼ 3), tandem HCT (n ¼ 10)
MM (100%)
MEL (n ¼ 29), maintenance
lenalidomide (n ¼ 3),
maintenance interferon-a
(n ¼ 1)
Age:
Median: 60
Range: 41-71
Gender:
M ¼ 17
F ¼ 15
Cross-sectional: mean
5.5 yr post-diagnosis
(range, 2-12)
EORTC QLQ C-30 Spearman’s correlations Sleep disruption
signiﬁcantly correlated
with serum IL-6 levels (P ¼
.02)
Boonstra et al.
(2011) [37]
Hospitalized HCT (N ¼ 69)
Allo (n ¼ 46), auto (n ¼ 23)
Disease sites not reported
Gender:
Male ¼ 41
Female ¼ 26
Cross-sectional; day 14
post-HCT (reﬂective of
2-week period)
ISI Descriptives and
chi-square tests
No insomnia ¼ 26%,
subthreshold insomnia ¼
48%, clinically signiﬁcant
insomnia (moderate) ¼
23%, clinically signiﬁcant
insomnia (severe) ¼ 3%.
Female and allo patients
were more likely to report
insomnia (no observed
differences in age).
Toileting (85%), staff
interruptions (80%),
physical symptoms (41%),
anxiety-self (39%), anxiety-
others (35%), and noise
(24%) most common
reasons for sleep
disruption.
Cohen et al.
(2012) [28]
Diverse HCT (N ¼ 164)
Allo (62%), auto (38%)
Disease sites not reported
HD (n ¼ 24), NHL (n ¼ 21), AML
(n ¼ 11)
38 Chemotherapy, 20
radiochemotherapy
Mean age: 45
Range ¼ 19-74
Gender:
M ¼ 56%
F ¼ 44%
Race:
Black ¼ 15%
Latino ¼ 23%
White ¼ 62%
Longitudinal; 8
assessments: pre-HCT to
day 100 post-HCT
MDASI Longitudinal linear mixed
models, correlations
Sleep disruption was 1 of
the 5 worst reported
symptoms; associated with
myeloablative regimens
and worse functional
status.
Danaher et al.
(2006) [24]
HCT (N ¼ 20 at baseline; N ¼ 17
post-HCT)
Auto ¼ 10 (59%), allo ¼ 7 (41%)
Lymphoma (23%), CML (6%),
AML (18%), ALL (6%), MM (29%),
myeloﬁbrosis (12%), plasma cell
leukemia (6%)
Mean age: 48.65 (23-64)
Gender:
M ¼ 45%
F ¼ 55%
Race:
White ¼ 35%, Black ¼ 40%,
Latino ¼ 15%, Asian ¼ 5%,
Other ¼ 5%
Longitudinal; pre-HCT and
5 and 8 d post-HCT
EORTC QLQ-C30 t-tests Sleep disruption
signiﬁcantly worse post-
HCT.
(continued on next page)
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Table 1
(continued )
Study Sample Demographics Time Frame Sleep Measures Statistical Analyses Main Relevant Findings
De Souza et al.
(2002) [77]
Allo-HCT (N ¼ 26)
All in complete remission
BM (n ¼ 13), PBSC (n ¼ 13)
CML (n¼ 21), AML (n¼ 3), MDS
(n ¼ 1), ALL (n ¼ 1)
Age:
Range ¼ 19-61
Gender:
M ¼ 14
F ¼ 12
Cross-sectional; mean of
1248 d post-HCT
WHOQOL-100: single-
item assessment: “Do
you have difﬁculties
with sleeping?”
Wilcoxon rank sum,
Kruskal-Wallis tests
No differences in sleep
between patients receiving
BM versus PBSC.
Diez-Campelo et al.
(2004) [39]
RIC allo-HCT (n ¼ 47), auto-HCT
(n ¼ 70)
AML (n ¼ 15), ALL (n ¼ 3), CML
(n ¼ 5), MDS (n ¼ 7), NHL (n ¼
3), HD (n ¼ 11), breast cancer
(n ¼ 6), MM (n ¼ 29), CLL (n ¼
4), amyloidosis (n ¼ 1)
FLU/MEL or FLU/BU (n ¼ 47),
BEAM (n ¼ 37), BU/MEL (n ¼ 8),
CY/carboplatin/thiotepa (n¼ 6),
MEL (n¼ 11), BU/CY (n¼ 7), CY/
TBI (n ¼ 1)
Age range, 16-70 Longitudinal; 6
assessments:
days þ7, þ14, þ21, þ90,
þ270, þ360 post-HCT
FACT sleep disruption
item: “I am sleeping
well”
Descriptives 14.3% of allo-RIC and 26.3%
of auto patients had
problems sleeping at 1 yr
post-transplant (P ¼ .29).
Enderlin et al.
(2013) [7]
Auto-HCT (N ¼ 12)
MM only
All participants on the Total
Therapy 3 protocol
Age:
Mean ¼ 61
Range ¼ 48-72
Gender:
M ¼ 10
F ¼ 2
Race:
White ¼ 10
African American ¼ 2
Cross-sectional; pre-HCT (1
assessment before, 1
assessment after chemo
cycle)
Polysomnography Descriptives Patients had a short sleep
time, excessive time spent
awake after sleep onset,
poor sleep efﬁciency, more
time in non-REM sleep, low
arterial oxygen saturation,
elevated periodic limb
movements as measured by
polysomnography.
Faulhaber et al.
(2010) [44]
Allo-HCT (N ¼ 61)
CML (37.7%), severe AA (21.3%),
AML (14.7), ALL (8.1%), NHL
(6.5%), HD (4.9%), Other (6.5%)
BU/CY (65.6%), RIC (18%), Cy
(9.8%), TBI/CY (6.6%)
Mean age: 36.5 (12.3)
Gender:
M ¼ 54.1%
F ¼ 45.9%
Cross-sectional; 1-10 yr
post-HCT
DSM-IV-TR criteria for
sleep disorders
Multivariate analysis The prevalence of sleep
disorders was 26.2%.
Multivariate analysis
indicated that busulfan-
cyclophosphamide was an
independent risk factor for
sleep disorders (included
sex and age).
Frick et al.
(2006) [23]
HCT (N ¼ 282)
Allo (35%), auto (62%)
AML/MDS (11.7%), ALL (5%),
CML (16%), HD (4.3%), NHL
(29.9%), MM (29.5%), Other
(3.6%); (97% hematologic
malignancies)
Age:
Median ¼ 48.5
SD ¼ 11.9
Gender:
F ¼ 39%
Cross-sectional; pre-HCT EORTC QLQ-C30 Pearson’s correlation
coefﬁcient
Compared patients with
sample of German
populationd36.6 patients
versus 16.4 population (no
SDs or SEs given).
Sleep disruption was
positively correlated with
problematic social support
(.183)
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Frodin et al.
(2011) [25]
Auto-HCT (N ¼ 111)
MM (n ¼ 56), lymphoma (n ¼
32), testicular cancer (n ¼ 3),
AML (n ¼ 2), multiple sclerosis
(n ¼ 1)
Conditioning: MEL (n ¼ 56),
BEAM (n ¼ 33), CEC (n ¼ 3), BU/
MEL (n ¼ 2), ZAM (Aavados,
ARA-C, melphalan) (n ¼ 2)
Based on 96 patients:
Age:
Mean ¼ 54 (12)
Gender:
M ¼ 62
F ¼ 34
Longitudinal; baseline,
week 1, week 2, week 3,
week 4, month 2, month 3,
month 6, year 1, year 1.5,
year 2, year 2.5, and year 3
EORTC QLQ-C30 The results are presented
using descriptive statistics,
means adjusted for gender
and age
Worst sleep disruption at 2
weeks post-HCT.
Sleep returned to baseline
levels by 2 mo post-HCT,
and remained relatively
stable thereafter through
the 3-year follow up.
Increase of 1.1 SD from pre-
HCT baseline to 2 wk follow
up.
Sleep disruption did not
differ between myeloma
and lymphoma patients.
Gallardo et al.
(2009) [61]
Allogeneic BMT (N ¼ 820; N ¼
150 QOL assessed)
Peripheral blood group (N ¼
410): AML (25.9%), ALL (24.1%),
CML (30.7%), MM (2.7%), NHL
(7.3%), HD (0.5%), MDS (7.8%),
Other (1%)
Bone marrow group (N ¼ 410):
AML (25.9%), ALL (24.1%), CML
(30.7%), MM (2.7%), NHL (7.3%),
HD (0.5%), MDS (7.8%), Other
(1%)
Peripheral blood group:
conditioning regimen with
TBI ¼ 198 (48.3%)
Bone marrow group:
conditioning regimen with
TBI ¼ 200 (48.8%)
Peripheral blood group
(N ¼ 410):
Age:
Median ¼ 35
Range ¼ 15-59
Gender:
M ¼ 58.9%
F ¼ 41.1%
Bone marrow group
(N ¼ 410):
Age:
Median ¼ 35
Range ¼ 15-59
Gender:
M ¼ 62.3%
F ¼ 37.7%
Retrospective;
follow up for alive patients:
median 43.8 mo for
patients receiving
peripheral blood, median
46.6 mo for patients
receiving bone marrow.
EORTC QLQ-C30,
Spanish Version
Chi-square, t tests There were no signiﬁcant
differences in sleep
difﬁculties reported
between patients who
received bone marrow (n ¼
73, M ¼ 15.9, SD ¼ 26.7)
versus peripheral blood
(n ¼ 77, M ¼ 18.2, SD ¼
26.2).
Gruber et al.
(2003) [29]
HCT (N ¼ 163)
Allo (85%), auto (12%), syngenic
(3%)
Included both disease-free and
relapsed patients
CLL/CML (n¼ 69), ALL/AML (n¼
58), Other (n ¼ 36)
Age at BMT:
Median ¼ 34 (9.2)
Gender:
M ¼ 62.6%
F ¼ 37.4%
Cross-sectional; within
16 yr post-HCT; (inclusion
criteria:  2 yr post-HCT,
transplanted b/w 1979-
1996)
SF-36, EORTC QLQ-C30,
SIP, Herschbach Stress
in Cancer Patients
Mann-Whitney analysis,
correlations
Unemployed, divorced, and
distressed patients
reported signiﬁcantly
greater sleep problems.
Grulke et al.
(2011) [26]
Quantitative review of 33
papers reporting EORTC scores
in HCT and covering 2800
patients
Range of participants (15-415),
total N ¼ 2804
Allo ¼ 52.6%
Auto ¼ 48.4%
Acute leukemia (28%), CML
(15.3%), other hematologic
diseases (42.1%), solid tumors
(14.8%)
Age Range (14-70)
Gender:
M ¼ 50.1%
Longitudinal; pre-HCT,
during hospitalization, at
discharge, up to 6 mo,
7-12 mo, 1-3 yr, >3 yr
EORTC QLQ-C30 Categorized data by time of
assessment, unweighted
arithmetic means.
Sleep problems increase
during inpatient stay then
return to baseline levels
after discharge (change of
25 points).
Sleep problems described
by authors as “persistent”
and at a “high level.”
(continued on next page)
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Table 1
(continued )
Study Sample Demographics Time Frame Sleep Measures Statistical Analyses Main Relevant Findings
Gulbrandsen et al.
(2004) [32]
Auto-HCT (N ¼ 274)
MEL/prednisone only (n¼ 203),
MM only
Not reported Longitudinal; pre-HCT, 1
mo, 6 mo, 12 mo, 24 mo,
and 36 mo post-HCT
EORTC QOLQ-C30 Linear regression model
with forward stepwise
selection
Reference population of
population-based study of
3000 Norwegians aged 18-
93 yr
Statistically signiﬁcant
difference between newly
diagnosed multiple
myeloma patients and
population norms, small in
magnitude with worse
scores in patients.
Hacker et al.
(2003) [30]
HCT (pre-HCT N ¼ 16, 6 wk
post-discharge N ¼ 8)
Allo (n ¼ 11), auto (n ¼ 5)
Lymphoma (n¼ 4), CML (n¼ 3),
AML (n ¼ 3), ALL (n ¼ 1), MM
(n ¼ 3), myeloﬁbrosis (n ¼ 3)
Mean age: 46.56
(11.31)
Gender:
M ¼ 50%
F ¼ 50%
Race:
White ¼ 10
Black ¼ 2
Latino ¼ 2
Native American ¼ 1
Asian ¼ 1
Longitudinal; 4
assessments:
pre-HCT, hospital
discharge, 2 weeks
post-discharge, 6 weeks
post-discharge
EORTC QLQ-C30 One-way repeated
measures ANOVA with
paired samples t-tests
and Bonferroni corrections
Sleep differences were
found between T1 (M ¼
41.67) and T2 (M ¼ 73.33)
(baseline to immediately
before discharge) and
between T2 and T3 (M ¼
33.33) (immediately before
discharge to 2 wk post-
hospitalization). T4 M ¼
33.33
Harder et al.
(2002) [78]
HCT (N ¼ 40)
Allo HCT (87.5%); allo MRD ¼
26, allo MUD ¼ 9, auto ¼ 5
ALL (n ¼ 8), AML (n ¼ 10), CML
(n ¼ 6), NHL (n ¼ 6), MDS (n ¼
4), MM (n ¼ 4), AA (n ¼ 2)
All had TBI up to 12 Gy,
intrathecal treatment (n ¼ 11),
conditioning regimen: CY (n ¼
12), ARA-C/CY (n ¼ 19), VP-16/
CY (n ¼ 9)
Age at HCT:
Mean ¼ 37.2
Range ¼ 15-55
Gender:
M ¼ 24
F ¼ 16
Cross-sectional; 22-82 mo
post-HCT
EORTC QLQ-C30 Descriptives Sleep disruption M ¼ 18.3
(SD ¼ 22.6)
Sleep disturbances were
one of the most commonly
reported complaints.
Hayden et al.
(2004) [53]
Sibling allo-HCT (N ¼ 51)
(original sample of 75 HCT
patients)
CY/TBI (32%); BU/CY (68%)
Based on 51 patients
alive in 2003:
Age at BMT:
Median ¼ 35
Range ¼ 14-55
Gender:
M ¼ 31
F ¼ 20
Cross-sectional; median of
98 mo post-HCT
EORTC QLQ-C30 Descriptives No difference in sleep
disruption between HCT
patients and reference
population.
Reference population not
described.
Hendriks &
Schouten
(2002) [45]
HCT (N¼ 52 at T1; N¼ 33 at T2)
Auto (81%), allo (19%) at T1
Relapse free
Lymphoma (40%), breast cancer
(29%), acute leukemia (29%)
Age:
Mean ¼ 41
Gender:
M ¼ 42%
F ¼ 58%
Longitudinal; mean of 2.5
yr and 4.5 yr post-HCT
EORTC QLQ-C30 Mann-Whitney U test,
correlations
No differences in sleep
disruption over time.
Patients reported more
sleep disruption than
general Norwegian
population.
Physicians tended to
underestimate sleep
problems.
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Hjermstad et al.
(2004) [33]
HCT (N ¼ 130), chemotherapy
patients (N ¼ 118)
Allo (n ¼ 61), auto (n ¼ 69)
HCT group: HD (n ¼ 15), high-
grade NHL (n ¼ 43), low-grade
NHL (n ¼ 11), CML (n ¼ 31),
AML (n ¼ 19), ALL (n ¼ 11)
Age at baseline:
Median ¼ 35
Range ¼ 17-55
Gender:
M ¼ 56%
F ¼ 44%
Longitudinal; pre-HCT and
3-5 yr post-HCT
EORTC QLQ-C30 Wilcoxontest or
1-way ANOVA as
appropriate. Conﬁdence
intervals for graphic
illustrations
No statistically signiﬁcant
changes in sleep disruption
from baseline to 3-5 yr in
allo or auto groups, but CT
group reported improved
sleep quality over time.
Allo patients reported
better sleep, auto worse
sleep than general
Norwegian population at
baseline and 3-5 yr post-
HCT.
Kiss et al.
(2002) [57]
Allo-HCT (N ¼ 28)
Included both disease-free and
relapsed patients
CML only
CY/TBI/ARA-C (n ¼ 27), BU/CY
(n ¼ 1)
Age:
Mean ¼ 32.6
Range ¼ 18.2-49.2
Gender:
M ¼ 16
F ¼ 12
Cross-sectional; mean of
13.2 yr post-HCT
Single item from a
symptom checklist
developed at the
hospital
Descriptives 21 of 26 patients were
mildly bothered by sleep
disruption, whereas 5 of 26
were moderately or
severely bothered.
Kopp et al.
(2005) [51]
HCT (N ¼ 34) and age- and sex-
matched noncancer control
subjects (N ¼ 68)
Allo-HCT (61.8%), auto-HCT
(38.2%)
Chronic leukemia (14.7%), acute
leukemia (47.1%), MM (8.8%),
MDS (5.9%), solid tumor (2.9%),
lymphoma (17.6%), sarcoma
(2.9%)
TBI fractionated (67.6%), TBI
single dose (8.8%), no (23.5%)
Mean age: 44.7 (9.4)
Gender:
M ¼ 50%
F ¼ 50%
Cross-sectional; patients
were at least 5 yr post-HCT
EORTC-QLQ C30 Mann-Whitney U-tests No signiﬁcant differences in
sleep between HCT patients
and healthy control
subjects; patients had
worse sleep by .06 SD.
Messerer et al.
(2008) [55]
Allo-HCT (N ¼ 121) and
chemotherapy (N ¼ 221)
Disease free
AML Only
Allogeneic BMT:
Age at diagnosis:
Median ¼ 38
Gender:
F ¼ 52%
Cross-sectional; HCT
patients were a median of
8 yr post-HCT; chemo
patients were a median of
9 yr post-chemo
EORTC QLQ-C30 Chi-square, stratiﬁed
Mantel-Haenszel, non
parametrics
No difference in sleep
disruption between allo
HCT patients and
chemotherapy patients (.06
SD).
Mosher et al.
(2011) [56]
HCT (N ¼ 406)
Auto (60.3%), allo (29.1%)
Relapse free
NHL (22.4%), HD (6.2%), AML/
CML (11.6%), ALL/CLL (3.4%),
MDS/MPS (8.4%), MM/
amyloidosis (33.7%), Other
(1.5%)
Mean age: 49.25 (12.82)
Gender:
M ¼ 51.5%
F ¼ 47.8%
Race:
White ¼ 83.7%, African
American ¼ 5.7%,
Hispanic ¼ 3.9%, West
Indian ¼ 1.5%,
Other ¼ 4.4%
Cross-sectional; mean of
21 mo post-HCT
FACT-BMT Percentage 80% of patients reported
sleeping well.
(continued on next page)
H
.S.L.Jim
et
al./
Biol
Blood
M
arrow
Transplant
20
(2014)
1465
e
1484
1473
Table 1
(continued )
Study Sample Demographics Time Frame Sleep Measures Statistical Analyses Main Relevant Findings
Pallua et al.
(2010) [47]
Allo-HCT (N ¼ 100)
AML (41%), CML (22%), ALL
(12%), lymphoma (6%), MDS
(6%), MM (4%), AA (4%), MPD
(2%), PNH (2%), CLL (1%)
Age:
Mean ¼ 46.3 (14.7)
Range ¼ 16-76
Gender:
M ¼ 55%
F ¼ 45%
Cross-sectional; mean of
95.4 mo post-HCT
EORTC QLQ-C30 Effect Sizes ¼ Cohen’s d, t-tests,
1-way ANOVA
No signiﬁcant association
between sleep disruption
and time since transplant.
Sleep disruption was
greater in patients with
ongoing GVHD compared
with patients with no
GVHD (ES ¼ .31; not
signiﬁcant).
Difference in sleep
disruption between HCT
patients and the reference
Austrian population (ES ¼
.31).
Rischer et al.
(2009) [4]
HCT (N ¼ 50 at pre-HCT, N ¼ 32
at day 100 post-HCT)
Allo (78%), auto (22%)
AML (36%), MM (22%), NHL
(14%), MDS (10%),
osteomyelofribrosis (10%),
Others (8%)
Mean age: 53.3 (12.6)
Gender:
M ¼ 74%
F ¼ 26%
Longitudinal; 3
assessments: pre-HCT,
during hospital stay, and
day 100 post-HCT
PSQI, sleep diary Chi-square, McNemar
tests, repeated measures
ANOVA Spearman’s
correlation coefﬁcients
Prevalence of sleep
disruption 32% before HCT,
77% during hospitalization,
28% at day 100.
During hospitalization:
difﬁculties maintaining
sleep was the most
reported sleep dimension
(81.8% moderate to severe,
mainly caused by noises
and toileting), then
nonrestorative sleep
(61.4%), difﬁculties falling
asleep (52.3%), difﬁculties
falling back asleep (47.7%),
and early a.m. awakenings
(20.5%).
Allo patients had
signiﬁcantly worse sleep
than auto patients.
Increases in sleep
disruption correlated with
increases in fatigue,
physical functioning,
treatment-speciﬁc distress
but not anxiety and
depression
Sherman et al.
(2003) [35]
Pre-BMT (N ¼ 61)
MM (85.3%), MGUS (8.2%),
amyloid (6.6%)
Age:
Mean ¼ 57 (12.3)
Gender:
M ¼ 63.9%
F ¼ 36.1%
Race:
White ¼ 91.8%
Other ¼ 8.2%
Cross-sectional; mean of
7.4 mo post-diagnosis; all
were assessed before BMT
Epworth Sleepiness
Scale
Descriptives, percentages,
and Spearman correlations
Pilot study
43.33% exceeded the
clinical cut-off of daytime
sleepiness.
Older age associated with
more daytime sleepiness.
Lower hemoglobin levels
associated with more
daytime sleepiness.
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Syrjala et al.
(2005) [52]
HCT survivors (N ¼ 137) and
age- and sex-matched control
subjects from the NHANES
study (N ¼ 4020)
Allo (88%), auto (12%)
CML (chronic phase) (45%), CML
(accelerated or blast crisis) (7%),
acute leukemia in remission
(14%), acute leukemia in relapse
(8%), lymphoma in remission
(10%), lymphoma in relapse
(7%), MDS (7%), Other (4%)
BMT survivors:
Mean Age: 34.6 (9.0)
Gender:
M ¼ 48%
Race:
White ¼ 95%
non-white,
non-Hispanic ¼ 3%
Hispanic ¼ 2%
Cross-sectional; 10 yr post-
HCT
Checklist of symptoms
developed for the study
Paired t-tests, McNemar,
Wilcoxon signed ranks tests
Alphas set at .01.
14% of survivors reported
moderate or severe sleep
problems compared with
9% of control subjects;
results were not
statistically signiﬁcant.
Watson et al.
(2004) [59]
HCT (N ¼ 171) and
chemotherapy (n ¼ 310)
Allo (n ¼ 97), auto (n ¼ 74)
CY (n ¼ 147), BU (n ¼ 26),
mesna (n ¼ 27), MEL (n ¼ 18),
TBI (n ¼ 135)
For all groups:
Age:
Median ¼ 39
Range ¼ 15-58
Gender:
M ¼ 45%
F ¼ 55%
Cross-sectional; at least 1 yr
post-HCT
EORTC QLQ-C30 Wilcoxon 2 sample test, t-test,
generalized linear models
45% of patients reported
sleep disruption.
Sleep disruption more
severe in older patients
than younger patients. No
difference in sleep
disruption between allo,
auto, or chemotherapy
groups. No differences in
sleep disruption between
males and females.
Wettergren et al.
(2008) [34]
Auto-HCT (N ¼ 22), compared
with Swedish population
norms
HD (n ¼ 1), NHL (n ¼ 3), AML
(n ¼ 6), MM (n ¼ 12)
Age:
Median ¼ 50
Range ¼ 31-66
Gender:
M ¼ 13
F ¼ 9
Longitudinal; pre-HCT and
1 yr post-HCT
EORTC QLQ-C30 McNemar test, paired t-test No signiﬁcant changes in
sleep disruption (ES ¼ .03),
no differences compared
with Swedish population
norms
Worel et al.
(2002) [46]
Allo or syngeneic HCT (N¼ 155)
Disease free
ALL/AML (n ¼ 9/43), CML (n ¼
56), MM (n ¼ 5), MDS (n ¼ 7),
NHL (n ¼ 15), AA (n ¼ 19),
testicular cancer (n ¼ 1)
TBI/CY, CY, CY/ATG, BU/CY
Age:
Median ¼ 34
Range ¼ 17-57
Gender:
M ¼ 86
F ¼ 69
Cross-sectional; at least 2 yr
post-HCT
EORTC QLQ-C30 Descriptives Divided patients 2-5 yr
post-HCT and more than 5
yr post-HCT. Of all patients,
45% had none or slight sleep
disruption, 43% had
moderate sleep disruption,
and 12% had severe sleep
disruption. Percentages
were comparable for
patients 2-5 yr post-HCT
and more than 5 yr post-
HCT.
AA indicates aplastic anemia; ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; ARA-C, cytarabine; ATG, anti-thymocyte globulin; BEAM, carmustine, etoposide, cytarabine, melphalan; BM, bone marrow; BU,
busulfan; CEC, cyclophosphamide, etoposide, carboplatin; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CY, cyclophosphamide; DSM-IV-TR, Diagnostic and statistical manual of mental disorders, 4th
edition, Text Revision; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; ES, effect size; FACT-BMT, Functional Assessment of Cancer TherapyeBone Marrow
Transplant; FLU, ﬂudarabine; HD, hodgkin disease; ISI, Insomnia Severity Index;MDASI, M.D. Anderson Symptom Inventory; MDS,myelodysplastic syndrome;MEL,melphalan;MGUS, monoclonal gammopathy of undetermined
signiﬁcance; MM, multiple myeloma; MOS, medical outcomes study; MPS, myeloproliferative syndrome; MRD, matched related donor; MUD, matched unrelated donor; NHL, non-Hodgkin’s lymphoma; PBSC, peripheral blood
stem cell; PNH, paroxysmal nocturnal hemoglobinuria; PSQI, Pittsburgh Sleep Quality Index; REM, rapid eye movement; RIC, reduced-intensity conditioning; SF-36, medical outcomes study short forme36; SIP, sickness impact
proﬁle; TBI, total body irradiation; VP-16, etoposide; WHOQOL100, World Health Organization Quality of Life Questionnaire 100.
H
.S.L.Jim
et
al./
Biol
Blood
M
arrow
Transplant
20
(2014)
1465
e
1484
1475
H.S.L. Jim et al. / Biol Blood Marrow Transplant 20 (2014) 1465e14841476get to sleep.” Maladaptive behaviors can include spending
prolonged time in bed, going to bed excessively early,
sleeping late, and staying in bed while no longer asleep.
Although these behaviors may initially be helpful, particu-
larly for people experiencing acute illness, eventually they
can contribute to irregular sleep patterns that result in
insomnia long after the patient has recovered from the acute
stressor or illness [43].
Only 1 study has examined the prevalence of sleep dis-
orders after transplant. Among 61 allogeneic HCT recipients
transplanted 1 to 10 years previously, 23% met criteria for a
diagnosis of insomnia and 3% for hypersomnia; no other
sleep disorders were observed [44]. In addition, no studies
have examined precipitating versus perpetuating factors of
sleep disruption after the acute transplant period. Never-
theless, 23 studies have reported on sleep disruption
outside the context of a diagnosed sleep disorder 90 days or
more after HCT. Notably, 20 assessed sleep using a single
item as part of a larger quality of life scale, whereas only 3
included validated measures of sleep. Seventeen studies
were cross-sectional; many included mixed samples of
autologous and allogeneic recipients who ranged widely in
terms of time from transplant. Thus, deﬁnitive conclusions
are difﬁcult to draw. However, available data suggest that
after peaking during the acute transplant period, the prev-
alence and severity of sleep disruption remains relatively
constant over time. Most studies found no signiﬁcant
change in sleep disruption between 1 and 10 years post-
transplant [44-47]. HCT survivors tend to report worse
sleep disruption compared with population norms and
noncancer comparison groups (ie, .33 to .39 SD) [45,47-50],
but the evidence is mixed [34,51-53]. A cross-sectional
study of allogeneic recipients 1 to 10 years post-transplant
found that 23% met criteria for clinical diagnosis of
insomnia [44], a rate similar to that of the general popula-
tion (ie, 22%) [54]. Furthermore, sleep disruption in patients
treated with HCT also does not differ from that in patients
treated with standard-dose chemotherapy at 8 to 9 years
post-treatment [55].
Although most evidence suggests no signiﬁcant change
in sleep disruption after the ﬁrst 100 days post-transplant,
estimates of the prevalence of sleep disruption in HCT pa-
tients vary widely. At 1 year post-HCT, 14% of patients
receiving allogeneic transplant with reduced-intensity
conditioning and 26% of patients receiving autologous
transplantation reported sleep disruption [39]. A mean of
2 years after transplant (range, 1 to 3 years), 20% of patients
reported sleep disruption [56]. In contrast, 2 to 5 years after
transplant, 49% of patients reported none or slight, 43%
reported moderate, and 8% reported severe sleep disrup-
tion [46]. Five or more years after transplant, 44%, 42%, and
14% of patients reported none or slight, moderate, and se-
vere sleep disruption, respectively [46]. A mean of 10 years
after transplant, 14% reported moderate or severe sleep
disruption [52]. An average of 13 years after transplant
(range, 10 to 18), 81% of patients reported they were not
bothered or only mildly bothered by sleep disruption,
whereas 19% reported they were moderately or severely
bothered [57]. In summary, the overall prevalence of any
sleep problems after the acute transplant period (ie, after
100 days) ranges from 14% to 51%, with the prevalence of
moderate problems ranging from 14% to 43% and severe
problems ranging from 8% to 14%. Variability in prevalence
rates likely stems from sample bias due to small sample
sizes in this literature.SOCIODEMOGRAPHIC AND CLINICAL PREDICTORS OF
SLEEP DISRUPTION AND DISORDERS
A clinically relevant question is how to identify HCT pa-
tients at risk for sleep disruption and disorders. Risk factors
for insomnia among cancer patients include female gender,
anxiety, surgical treatment, and maladaptive beliefs about
sleep [58]. Among HCT patients, 1 small study observed that
conditioning with busulfan and cyclophosphamide was a
risk factor for insomnia [44]. Risk factors for OSA in the
general population include obesity, type 2 diabetes,
congestive heart failure, kidney disease, and treatment-
refractory hypertension [17].
Some of the risk factors that lead to sleep disruption and
disorders may be more prevalent after HCT (eg, diabetes,
hypertension). Risk factors for RLS in the general population
include female gender, pregnancy, low blood ferritin, high
alcohol intake, poor renal function, high blood glucose levels,
and obesity [42]. Although HCT patients are more likely to
have high (rather than low) blood ferritin, they may expe-
rience high blood glucose levels and weight gain because of
treatment with corticosteroids. In addition, several autoim-
mune diseases are risk factors for RLS (eg, rheumatoid
arthritis, multiple sclerosis, Crohn’s disease), suggesting that
high levels of inﬂammation may play a role [42]. These
ﬁndings have relevance for GVHD as a potential risk factor for
RLS, although data are lacking. Thus, in general, risk factors
for clinical sleep disorders include female gender, obesity,
comorbidities such as diabetes and poor renal function,
anxiety, and maladaptive beliefs about sleep.
Regarding sleep disruption outside the context of a
diagnosed sleep disorder, evidence suggests that women are
more likely to endorse sleep problems than men [44]. Evi-
dence also suggests that sleep disruption is more severe in
older patients [44,59]. Systemic inﬂammation has been
associated with worse sleep, although the sample was small
and primarily consisted of autologous HCT recipients [60].
Regarding transplant type, allogeneic recipients tend to
report better sleep than autologous recipients before trans-
plant and 3 years later [33] but worse sleep during the acute
transplant period [4,28,37]. Among allogeneic recipients,
signiﬁcant associations between GVHD and sleep disruption
have not been found [47]; however, literature examining this
relationship is sparse. Other clinical variables, such as bone
marrow versus peripheral blood stem cell transplantation,
have not shown signiﬁcant differences in the prevalence of
sleep problems [61]. Nevertheless, comparisons by GVHD
and type of blood product are likely underpowered because
of small sample sizes. Regarding psychosocial risk factors,
research is scarce, but available studies suggest that divorced
HCT recipients have higher rates of sleep problems than
unmarried patients [29] and unemployed recipients report
worse sleep than recipients who are working at the time of
assessment [29,49]. In addition, distress, depression, and
anxiety are associated with worse sleep [29]. Thus, available
evidence suggests that risk factors for sleep disruption
outside the context of a diagnosed sleep disorder are older
age, female gender, divorce, unemployment, distress, and
autologous transplant. Additional research is needed to
conﬁrm these ﬁndings in larger samples.
TREATMENT OF SLEEP DISRUPTION AND DISORDERS
Treatments for sleep disorders are varied and depend on
the underlying cause. Regarding insomnia, the National In-
stitutes of Health Consensus and the American Academy of
Sleep Medicine recommend cognitive behavioral therapy for
Table 2
Online Resources for Sleep Disorders and Disruption
Type of Intervention Relevant Disorder(s) Resource Internet Address Description Evidence Base Cost
Cognitive-behavioral
interventions
Insomnia SHUTi www.shuti.me  Interactive online program that includes videos
from insomnia experts, interactive quizzes, and
vignettes dealing with real-life sleep issues
 Progress is tracked
 Provides recommendations tailored to individuals’
sleep difﬁculties
Cancer patients
Adults
$129.00 For 16 weeks
of access
Insomnia RESTORE www.restorecbt.com  Treatment consists of 5 modules with instructive
videos and downloadable MP3 ﬁles
Adults Cost unspeciﬁed. Made
available through patients
health care provider.
Also works with health
insurance providers.
Insomnia Sleepio www.sleepio.com  Interactive online treatment is delivered by a
virtual therapist and consists of 6 personally
tailored interactive stages
 Progress is tracked and each stage is adjusted
accordingly
Adults Three payment plan options:
$9.99 per week, $79.99
for 12-week access, and
$119.99 for 24-week access.
Education about
insomnia and
treatment
All sleep disorders National Sleep
Foundation
www.sleepfoundation.org  Comprehensive information about sleep, support
groups, video and audio library, and sleep
professional location assistance
N/A Free
All sleep disorders Sleep Education www.sleepeducation.com  Comprehensive information about sleep
difﬁculties, video archive, and sleep professional
location assistance
N/A Free
All sleep disorders Your Sleep http://yoursleep.aasmnet.org  Comprehensive information about sleep,
self-administered sleep assessments, downloadable
sleep diary, online forum, and sleep professional
location assistance
N/A Free
OSA American Sleep
Apnea Association
http://sleepapnea.org/  Self-administered screening for OSA, information
about OSA, and information on support groups
for people with OSA
N/A Free
RLS Willis-Ekbom Disease
Foundation
http://www.rls.org/  Self-administered screening for RLS, information
about RLS, and information on support groups
for people with RLS
N/A Free
Cancer-speciﬁc
education about
insomnia and
treatment
Insomnia National Cancer
Institute
www.cancer.gov  Information speciﬁc to cancer related sleep
difﬁculties, symptom management tips, and
modules
 To ﬁnd sleep information type “sleep” into the
“search” box located on the upper righthand
corner on the home page
N/A Free
General sleep health American Cancer
Society
www.cancer.org  Information speciﬁc to cancer-related sleep
difﬁculties and treatment and symptom
management tips, and modules
 Available in Spanish.
 To ﬁnd sleep information type “sleep” into the
“search” box located on the center on the home
page
N/A Free
Insomnia Cancer Support
Community
www.cancersupportcommunity.org  Information speciﬁc to cancer-related sleep
difﬁculties, tips for managing insomnia,
hyperinsomnia, and nightmares
 To ﬁnd sleep information type “sleep” into the
“search” box located on the upper righthand
corner on the home page
N/A Free
(continued on next page)
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research has shown that CBT-I can be as effective as some
pharmacologic agents in the treatment of insomnia in the
general population [62]. There have been no studies to date
on the effectiveness of CBT-I speciﬁcally in patients under-
going HCT. Nevertheless, numerous well-designed studies in
cancer patients have shown that CBT-I can indeed be effec-
tive in improving objectively (eg, actigraphy) and subjec-
tively measured (eg, self-reported insomnia severity and
sleep diaries) sleep disruption during and after treatment
[63]. Therapeutic effects of CBT-I have been found to last for
up to 12 months in cancer survivors [63]. Online resources
for sleep disruption and disorders, including Internet-based
CBT-I, are shown in Table 2.
The American Academy of Sleep Medicine recommends
that when pharmacotherapy is used for insomnia, short- or
intermediate-acting benzodiazepine receptor agonists or
ramelteon (Rozerem), a melatonin receptor agonist, be pre-
scribed [16]. Examples of medications in various drug classes,
along with indications, contraindications, and long-term ef-
ﬁcacy from randomized placebo-controlled trials in patients
with primary insomnia, are listed in Table 3. The choice of
medications within a class of drugs should depend on pa-
tients’ symptomatology (eg, delayed sleep onset versus dif-
ﬁculty maintaining sleep), patients’ preferences regarding
use of a controlled substance, and contraindications of the
medication. It should be noted that no studies have exam-
ined pharmacotherapy for insomnia speciﬁcally in the
context of HCT.
The ﬁrst-line treatment for OSA is positive airway pres-
sure, which pneumatically splits the upper airway through a
device worn on the nose and/or mouth during sleep [17].
Additional therapies for OSA include surgery, oral appliances,
implanted upper airway stimulation devices, and behavioral
strategies to lose weight, exercise, adjust sleep position, and
avoid alcohol and sedatives at bedtime [17]. No studies have
examined treatments for OSA among patients treated with
HCT.
The ﬁrst-line treatment for RLS includes the dopamine
agonists pramipexole and ropinirole [18]. Additional medi-
cation options include levodopa with dopa decarboxylase
inhibitor, opioids, gabapentin, enacarbil, and cabergoline.
Although no treatment studies for RLS have been conducted
speciﬁcally among HCT recipients, pregabalin shows promise
for treating RLS secondary to neuropathy and/or neuropathic
pain [64]. Also, some data suggest that some antidepressants
may contribute to increased risk of RLS, including citalopram,
paroxetine, amitriptyline, mirtazapine, and tramadol,
although evidence is mixed [18]. Thus, avoidance or
discontinuation of use of these medications should be
considered in patients with RLS.
To our knowledge, only 1 behavioral intervention study
has been conducted in HCT recipients with the primary aim
of improving sleep disruption outside the context of a diag-
nosed sleep disorder [65]. In addition, 5 behavioral inter-
vention studies have examined sleep disruption as a
secondary outcome [66-70]. All 6 studies were randomized
trials of psychoeducation, stress management, aerobic exer-
cise, and resistance training alone or in combination during
the inpatient period; 1 study also followed patients for
6 months post-HCT [66]. Samples consisted of patients
receiving allogeneic HCT [67,69], autologous HCT [70], tan-
dem autologous HCT [65], and either allogeneic or autolo-
gous HCT [66,67]. All reported null results for sleep
disruption compared with usual care. Sample sizes ranged
Table 3
Medications Recommended for Treatment of Insomnia by the American Academy of Sleep Medicine [16]
Drug Class Agent(s) FDA-Approved
for Sleep Onset
[79]
FDA-Approved for
Sleep Maintenance
[79]
Controlled
Substance
Generic
Available
Relevant Contraindications
Include [79]
RCT-Demonstrated
Efﬁcacy for Insomnia
up to
Relevant Drug Interactions
Short/intermediate
acting benzodiazepine
receptor agonists
Eszopiclone
(Lunesta)
Yes Yes Yes Yes Impaired motor/cognitive
performance with higher
dosage in elderly
6 mo CNS depressants, rifampicin,
ketoconazole
Temazepam
(Restoril)
Yes Yes Yes Yes Oversedation, confusion,
ataxia with higher dosage
in elderly
8 wk CNS depressants, hypnotics,
diphenhydramine
Triazolam
(Halcion)
Yes No Yes Yes Compromised respiratory
function, renal or hepatic
impairment, pulmonary
insufﬁciency
5 wk Ketoconazole, itraconazole,
nefazodone, HIV protease
inhibitors, medications that
impair the oxidative
metabolism mediated by CYP3A4
Zaleplon
(Sonata)
Yes No Yes Yes Conditions affecting
metabolism or hemodynamic
responses or compromised
respiratory function
4 wk Promethazine; rifampin; CYP3A4
inducers; CYP3A4 inhibitors;
cimetidine; additive CNS
depression with other
psychotropic medications,
anticonvulsants, antihistamines,
narcotic analgesics, anesthetics,
ethanol, and other CNS depressants
Zolpidem
(Ambien)
Yes No Yes Yes Compromised respiratory
function, conditions affecting
metabolism or hemodynamic
responses, renal or hepatic
impairment, risk of impaired
motor/cognitive performance
in elderly
8 mo CNS depressants; other sedative-
hypnotics; imipramine;
chlorpromazine; alcohol;
sertraline; CYP3A4 inhibitors;
rifampin; ﬂuoxetine; ketoconazole
Zolpidem
(Ambien CR)
Yes Yes Yes Yes Compromised respiratory
function, conditions affecting
metabolism or hemodynamic
responses, renal or hepatic
impairment, risk of impaired
motor/cognitive performance
in elderly
6 mo CNS depressants; other sedative-
hypnotics; imipramine;
chlorpromazine; alcohol;
sertraline; CYP3A4 inhibitors;
rifampin; ﬂuoxetine; ketoconazole
Zolpidem
(Intermezzo)
No Yes Yes No Compromised respiratory
function, risk of impaired
motor/cognitive performance
in elderly
4 wk CNS depressants; imipramine;
chlorpromazine; rifampin;
ketoconazole
Melatonin receptor
agonist
Ramelteon
(Rozerem)
Yes No No Yes Hepatic impairment, may affect
reproductive hormones
6 mo CYP inducers, CYP1A2 inhibitors,
CYP3A4 inhibitors, CYP2C9
inhibitors; donepezil; doxepin;
zolpidem; CNS depressants; alcohol
Intermediate/long acting
benzodiazepine
receptor agonist
Clonazepam
(Klonopin)
No No Yes Yes Renal or hepatic impairment,
respiratory diseases, elderly
patients, glaucoma
None CYP450 inducers; propantheline;
CYP3A inhibitors; alcohol;
narcotics; barbiturates; hypnotics;
antianxiety agents; phenothiazines;
thioxanthene; butyrophenone
antipsychotics; MAOIs; TCAs;
(continued on next page)
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Table 3
(continued )
Drug Class Agent(s) FDA-Approved
for Sleep Onset
[79]
FDA-Approved for
Sleep Maintenance
[79]
Controlled
Substance
Generic
Available
Relevant Contraindications
Include [79]
RCT-Demonstrated
Efﬁcacy for Insomnia
up to
Relevant Drug Interactions
anticonvulsant drugs; CNS
depressants; valproic acid
Estazolam (ProSom,
Eurodin)
Yes No Yes Yes Renal or hepatic impairment,
compromised respiratory
function, depression
1 wk CNS-acting drugs; anticonvulsants;
antihistamines; alcohol; barbiturates;
MAOIs; narcotics; phenothiazines;
psychotropic medications; CNS
depressants; smoking; CYP3A
inhibitors; CYP3A inducers
Flurazepam
(Dalmane)
Yes Yes Yes Yes Depression, hepatic or renal
impairment, pulmonary
insufﬁciency
3 wk CNS depressants; alcohol
Lorazepam
(Ativan)
No No Yes Yes Compromised respiratory
function, impaired renal or
hepatic function, elderly
None CNS depressants; clozapine;
valproate; probenecid; theophylline;
aminophylline
Sedating low-dose
antidepressant
Amitriptyline No No No Yes Liver dysfunction None Guanethidine; CNS depressants;
CYP2D6 inhibitors; TCAs; SSRIs;
“caution with thyroid drugs”;
disulﬁram; ethchlorvynol;
anticholinergics; sympathomimetics;
neuroleptics; cimetidine
Doxepin (Silenor)
3-6 mg
No Yes No Yes Compromised respiratory
function
12 wk Alcohol; CNS depressants; sedating
antihistamines; CYP2C19 inhibitors;
CYP2D6 inhibitors; CYP1A2 inhibitors;
CYP2C9 inhibitors; cimetidine;
tolazamide; sertraline
Mirtazapine
(Remeron)
No No No Yes Neutropenia and hyponatremia
reported, renal or hepatic
impairment, conditions affecting
metabolism or hemodynamic
responses, elderly, may cause
orthostatic hypotension
None MAOIs; serotonergic drugs; drugs
affecting hepatic metabolism; CYP
enzyme inducers; drugs metabolized
by or inducers of cytochrome P450;
antihypertensives known to cause
hyponatremia; phenytoin;
carbamazepine; hepatic metabolism
inducers; cimetidine; ketoconazole;
cimetidine; alcohol; diazepam;
CYP3A4 inhibitors; HIV protease
inhibitors; azole antifungals;
erythromycin; nefazodone; warfarin
Trazodone
(Oleptro)
No No No Yes Hypotension and syncope
reported, elderly, renal or hepatic
impairment, hyponatremia may
occur
1 wk Serotonergic drugs; drugs which
impair serotonin metabolism;
antipsychotics; dopamine agonists;
serotonin precursors; CYP3A4
inhibitors; Carbamazepine; MAOIs;
alcohol; barbiturates; CNS
depressants; warfarin;
antihypertensives; NSAIDs; aspirin;
drugs that affect coagulation or
bleeding; diuretics; drugs that
prolong QT interval
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Trimipramine
(Surmontil)
No No No Yes Liver dysfunction, elderly None Serotonergic drugs; drugs which
impair serotonin metabolism;
caution on patients on thyroid
medication; guanethidine;
cimetidine; alcohol; catecholamines;
anticholinergics; sympathomimetic
amines; local decongestants; local
anesthetics containing epinephrine;
atropine; CYP2D6 inhibitors; SSRIs;
TCAs
Other prescription
drugs
Gabapentin
(Neurontin)
No No No Yes Liver dysfunction, hepatic
impairment
None Maalox; naproxen sodium;
hydrocodone
Olanzapine
(Zyprexa)
No No No Yes Hepatic impairment; prostatic
hypertrophy; may cause
orthostatic hypotension;
leukopenia, neutropenia, and
agranulocytosis reported; may
cause cognitive and motor
impairment
None Diazepam; alcohol; carbamazepine;
omeprazole; rifampin; CYP1A2
inducers; ﬂuoxetine; ﬂuvoxamine;
other centrally-acting drugs;
potentially hepatotoxic drugs;
antihypertensives; levodopa;
dopamine agonists; anticholinergic
drugs; parenteral benzodiazepines
Tiagabine
(Gabitril)
No No No Yes Incapacitating weakness
reported
1 night Valproate; carbamazepine; phenytoin;
phenobarbital; ethanol; triazolam;
drugs that lower seizure threshold
(antidepressants, antipsychotics,
stimulants, narcotics); drugs that
induce or inhibit hepatic
metabolizing enzymes; highly
protein-bound drugs
Quetiapine
(Seroquel)
No No No Yes May induce orthostatic
hypotension; leukopenia,
neutropenia, and agranulocytosis
reported; may impair physical/
mental abilities
None Centrally-acting drugs; alcohol;
CYP3A4 inhibitors; CYP3A4
inducers; antihypertensives;
levodopa; dopamine agonists;
drugs known to cause electrolye
imbalance; drugs known to prolong
QTc interval (eg, antiarrhythmics,
antipsychotics, antibiotics);
anticholinergic medications
FDA indicates U.S. Food and Drug Administration; RCT, randomized controlled trial; CNS, central nervous system; MAOI, monoamine oxidase inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.
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disruption does not improve with exercise or stress man-
agement during the inpatient period. Additional studies
focusing on long-term transplant survivors are needed.DISCUSSION
Sleep disruption is a common problem among HCT re-
cipients. In addition to being distressing in its own right,
sleep disruption may affect other clinically important out-
comes. For example, previous research in patients undergo-
ing standard-dose chemotherapy suggests that sleep
disruption occurs ﬁrst in a cascade of symptoms, contrib-
uting to increases in fatigue and in turn depression [71]. In
addition, preliminary research suggests that sleep disruption
may negatively impact immune response and reconstitution
[72], although this has not been demonstrated in the context
of HCT. Taken together, these studies argue for early inter-
vention to manage sleep disruption and disorders in HCT
recipients.
Effective management of sleep disruption may be difﬁ-
cult in the inpatient setting due to environmental factors
that can interrupt sleep. Environmental interventions to
improve sleep among inpatients may be more effective than
patient-based interventions (eg, minimizing of nighttime
vital signs monitoring). A study conducted by Sharda et al.
[73] suggests that vital sign monitoring might not be
necessary for HCT patients with low-risk proﬁles (ie, lack of
daytime fever and central nervous system complaints) and
may lead to improved sleep and health. In contrast, use of a
hypnotic (zolpidem) has been associated with increased
inpatient falls [74].
Regarding outpatient sleep management, several phar-
macologic and behavioral management options are available.
National Comprehensive Cancer Network Survivorship
guidelines recommend screening for sleep disruption at
regular intervals, particularly when there has been a change
in clinical status or treatment [75]. Insomnia causing
decreased daytime functioning, worse quality of life, wors-
ening of complaints, or distress to the patient should be
treated with CBT-I, sleep hygiene education, medication,
and/or referral to a sleep specialist [75]. In light of the strong
evidence base for CBT-I in cancer patients, we believe it
should be considered as a ﬁrst choice for treatment of
chronic sleep disruption in HCT recipients. CBT-I lacks side
effects, medication interactions, and potential for abuse. In
addition, it may be more acceptable than pharmacologic
treatment for HCT recipients who would prefer to avoid
additional medication. Referral to a clinical psychologist
board certiﬁed in behavioral sleepmedicine is recommended
for patients interested in CBT-I. For patients who are un-
willing or unable to engage in CBT-I or for whom it is not
effective or feasible, pharmacologic treatment is a viable
alternative. Previous research has found that sleep medica-
tions commonly prescribed to cancer patients are lorazepam
(31.4%) and zolpidem (29.4%) [76], although, as noted pre-
viously, no evidence exists for their effectiveness in HCT re-
cipients. Patients with OSA should be referred to a sleep
medicine physician, whereas patients with RLS should be
treated with medication and/or referred to a sleep medicine
physician [75]. Because of the specialized needs of HCT pa-
tients, it is advisable that patients with sleep disorders be
managed by an interdisciplinary team consisting of the
transplant physician, sleep medicine physician, and/or clin-
ical psychologist.Additional research is clearly needed regarding sleep
disruption in HCT recipients. Longitudinal studies should be
conducted to determine prevalence, chronicity, and natural
course of sleep disruption and disorders secondary to HCT
using well-validated objective and self-report measures of
sleep as well as clinical diagnostic criteria. The prevalence of
sleep disruption and disorders in HCT recipients should be
compared with population normative data, because they are
also common among individuals without cancer. Future
studies should also aim to identify genetic, sociodemo-
graphic, and clinical risk factors for sleep disruption and
disorders secondary to HCT. Well-designed randomized
controlled trials are needed to test the efﬁcacy of behavioral
and pharmaceutical management of sleep problems in HCT
recipients.
In summary, sleep disruption is a common, distressing,
and under-recognized problem among HCT recipients. Clin-
ical efforts to proactively manage sleep disruption and dis-
orders have the potential to improve overall quality of life in
this population. Until more research is conducted with a
speciﬁc focus on HCT recipients, strategies to manage sleep
disruption and disorders should be adapted from the current
evidence base in cancer patients and the general population.
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